Biochemical markers in Alzheimer’s disease clinical trials

Effects of Memantine on Cerebrospinal Fluid Biomarkers of Neurofibrillary Pathology

(2017) Lidia Glodzik et al.   JOURNAL OF ALZHEIMERS DISEASE

A γ-secretase inhibitor decreases amyloid-β production in the central nervous system

(2009) Randall J. Bateman et al.   ANNALS OF NEUROLOGY

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

(2009) Leslie M. Shaw et al.   ANNALS OF NEUROLOGY

CSF Biomarkers

(2009) Niklas Mattsson et al.   Annals of the New York Academy of Sciences

The Uses of Biomarkers in Drug Development

(2009) Orest Hurko   Annals of the New York Academy of Sciences

A Specific Enzyme-Linked Immunosorbent Assay for Measuring β-Amyloid Protein Oligomers in Human Plasma and Brain Tissue of Patients With Alzheimer Disease

(2009) Weiming Xia et al.   ARCHIVES OF NEUROLOGY

Blood-Based Microcirculation Markers in Alzheimer's Disease–Diagnostic Value of Midregional Pro-atrial Natriuretic Peptide/C-terminal Endothelin-1 Precursor Fragment Ratio

(2009) Katharina Buerger et al.   BIOLOGICAL PSYCHIATRY

Rapid Progression from Mild Cognitive Impairment to Alzheimer’s Disease in Subjects with Elevated Levels of Tau in Cerebrospinal Fluid and the APOE ε4/ε4 Genotype

(2009) Elin S. Blom et al.   DEMENTIA AND GERIATRIC COGNITIVE DISORDERS

Future Screening for Incipient Alzheimer’s Disease – The Influence of Prevalence on Test Performance

(2009) Niklas Mattsson et al.   EUROPEAN NEUROLOGY

CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment

(2009) Niklas Mattsson   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

How can we recognize “disease modification” effects?

(2009) E. R. Siemers   Journal of Nutrition Health & Aging

Existing plaques and neuritic abnormalities in APP:PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575

(2009) Monica Garcia-Alloza et al.   Molecular Neurodegeneration

Update on amyloid‐βhomeostasis markers for sporadic Alzheimer's disease

(2009) Henrik Zetterberg   SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION

Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease

(2008) Ahmadul Kadir et al.   ANNALS OF NEUROLOGY

Phase 2 Safety Trial Targeting Amyloid β Production With a γ-Secretase Inhibitor in Alzheimer Disease

(2008) Adam S. Fleisher et al.   ARCHIVES OF NEUROLOGY

The discovery and early validation of novel plasma biomarkers in mild-to-moderate Alzheimer's disease patients responding to treatment with rosiglitazone

(2008) Emma L. Akuffo et al.   BIOMARKERS

Amyloid   Protein Dimer-Containing Human CSF Disrupts Synaptic Plasticity: Prevention by Systemic Passive Immunization

(2008) I. Klyubin et al.   JOURNAL OF NEUROSCIENCE

First Demonstration of Cerebrospinal Fluid and Plasma A  Lowering with Oral Administration of a  -Site Amyloid Precursor Protein-Cleaving Enzyme 1 Inhibitor in Nonhuman Primates

(2008) S. Sankaranarayanan et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial

(2008) Lars Lannfelt et al.   LANCET NEUROLOGY

Biochemical markers in persons with preclinical familial Alzheimer disease

(2008) J. M. Ringman et al.   NEUROLOGY

PET imaging of amyloid deposition in patients with mild cognitive impairment

(2007) Anton Forsberg et al.   NEUROBIOLOGY OF AGING